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Dendritic cell (DC) migration from the periphery to
lymph nodes is regulated by the pattern of genes ex-
pressed by DCs themselves and by signals within
the surrounding peripheral environment. Here, we re-
port that DCmobilization can also be regulated by sig-
nals initiated within the downstream lymph nodes,
particularly when lymph nodes enlarge as a conse-
quence of immunization. Lymph node B lymphocytes
orchestrate expansion of the lymphatic network within
the immunized lymph node. This expanded network in
turn supports increased DCmigration from the periph-
ery. These results reveal unique relationships between
B cells, lymphatic vessels, and migratory DCs. Knowl-
edge that DC migration from the periphery is aug-
mented by B cell-dependent signals reveals new po-
tential strategies to increase DC migration during
vaccination.
Introduction
Dendritic cells (DCs) stimulate the expansion of cognate
antigen-specific naive T cells and thereby initiate pri-
mary immune responses (Banchereau and Steinman,
1998; Lanzavecchia and Sallusto, 2001). Antigen-bear-
ing DCs typically gain access to lymph nodes (LNs)
and the T cell zone therein via emigration through affer-
ent lymphatic vessels that are ubiquitously present in
peripheral tissues (Kupiec-Weglinski et al., 1988; Ran-
dolph et al., 2005). Interfering with DC trafficking from
tissues to LNs often leads to marked defects in the initi-
ation of immune responses (Angeli et al., 2004b; Fo¨rster
et al., 1999). Furthermore, in clinical trials, the unexpect-
edly poor mobilization of adoptively transferred DCs to
the LNs has limited the efficacy of therapeutic vaccines
(Berger and Schultz, 2003; Morse et al., 1999).
To date, virtually all research on DC mobilization from
the periphery has focused on mechanisms that DCs em-
ploy to reach lymphatic vessels. For example, lymphatic
vessels express the chemokine CCL21Leu (Vassileva
*Correspondence: veronique.angeli@mssm.eduet al., 1999), which may readily attract DCs that express
its cognate chemokine receptor CCR7, a receptor in-
duced upon DC maturation and essential for DC mobili-
zation to LNs (Fo¨rster et al., 1999; Martin-Fontecha et al.,
2003). Thus, naturally, considerations of how DC migra-
tion might be manipulated have so far focused on at-
tempts to stimulate the peripheral environment where
DCs are induced to enter lymphatics (Martin-Fontecha
et al., 2003).
When a robust immune response develops, the cellu-
larity of LNs expands, allowing for increased sampling
between T cells and DCs. During this expansion, and in-
deed in LNs that naturally vary in size in different ana-
tomic locations, a relatively constant ratio between
DCs and lymphocytes is often maintained. It remains un-
clear how, and even whether, trafficking signals are or-
chestrated to balance the number of lymphocytes and
DCs entering the LNs via two distinct routes, the special-
ized high endothelial blood venules (HEVs) (Jalkanen
et al., 1986) and afferent lymphatics, respectively. A pri-
ori, it seems unlikely that signals in the LN itself could
stimulate DC mobilization from an ‘‘upstream’’ location
in a peripheral tissue, since movement of molecules
(like chemokines) from the LN to the periphery would
be limited by the opposing direction of lymph flow and
the valve system within collecting lymphatic vessels
(Schmid-Schonbein, 1990). Nonetheless, we examined
whether DC migration might be affected by events that
occur in the draining LNs. Our findings reveal that, in-
deed, signals initiated within activated draining LNs
can increase emigration of DCs. This process is depen-
dent on the growth of lymphatic vessels in the activated
LNs and requires, unexpectedly, the recruitment of B
cells to the affected LN to coordinate the expansion of
lymphatics.
Results
Inflamed Lymph Nodes Enhance DC Migration
from the Periphery
We immunized mice with the model antigen keyhole lim-
pet hemocyanin (KLH) emulsified in complete Freund’s
adjuvant (CFA), a protocol that triggers a vigorous LN re-
sponse and expansion. Then we induced DCs to migrate
from a peripheral location upstream of the same stimu-
lated LN but very distal to the local site of CFA/KLH
administration (Figure 1A). Specifically, CFA/KLH was in-
jected in the front footpads, and DC migration was stim-
ulated in the scapular area skin of the mice (Figure 1A).
The site of CFA/KLH injection was characterized by
dramatic inflammatory infiltrates and local vascular en-
dothelium-induced expression of VCAM-1 (Figure 1B),
known to be expressed in response to inflammatory
stimuli (Bevilacqua, 1993). These signs of inflammation
were not observed in the scapular skin where we trig-
gered DC migration (Figure 1B), illustrating that mobi-
lized DCs from this site were not directly exposed to
the inflammatory mediators generated in the footpad.
The size and cellularity of the brachial LN draining the
footpad injected with CFA/KLH increased, as expected,
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204Figure 1. Expansion of the Lymph Nodes and Consequence on Migration of Endogenous DCs
(A) Diagram depicts the experimental protocol used, showing the sites of immunization with CFA/KLH, FITC application, and the location of the
draining LNs (brachial LNs).
(B) Skin sections from the front footpad (site of immunization) and from the scapular area (site of DC mobilization), collected 3 days after CFA/
KLH injection, were stained for histological analysis or with anti-VCAM-1 and anti-CD31.
(C) LN cellularity and the number of migrated skin DCs in brachial LNs were evaluated 18 hr after FITC painting. Significant differences are des-
ignated by *p < 0.05. Results are representative of 10 experiments (nR 3). LN sections were stained for 2A1, a marker of matured DCs.
(D) Nonimmunized and immunized mice were treated with or without BrdU for 48 hr 1 day before FITC application, and incorporation of BrdU by
CD11c+FITC2 and CD11c+FITC+ DCs was analyzed. Three animals were independently analyzed for each group, and one representative analysis
is shown. All scale bars, 20 mm.compared with nonimmunized or contralateral brachial
LNs, which did not expand (Figure 1C). Peak LN expan-
sion, resulting in a 3- to 6-fold increase in total LN cells,
was observed 4 days after immunization with CFA/KLH
(Figure 1C) or with CFA alone (data not shown).Mobilization of DCs from a skin site upstream of the
immunized LN, but far from the site of CFA/KLH admin-
istration (Figure 1A and 1B), was initiated by epicutane-
ous application of FITC in a contact sensitizing solution
(Kripke et al., 1990). The number of FITC+ DCs that were
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sive to CFA/KLH compared to unstimulated or contralat-
eral LNs (Figure 1C). The increase in DC migration was
directly proportional to the extent of LN expansion. In
both nonimmunized and immunized mice, migrated
DCs, identified by the coexpression of FITC and 2A1
(Robbiani et al., 2000), localized in the T cell area of
LNs 18 hr after FITC sensitization (Figure 1C). Similar
outcomes occurred when we used another model of
LN expansion triggered by bacteria rather than CFA
(McLachlan et al., 2003) (see Figure S1 in the Supple-
mental Data available with this article online).
To investigate whether more peripheral DCs may truly
migrate to inflamed LNs as suggested by these data, we
conducted several experiments to eliminate alternative
interpretations. First, because DCs can divide in lym-
phoid organs (Kabashima et al., 2005), we investigated
whether the increased number of FITC+ DCs in LNs
from immunized mice could result from proliferation of
these cells within LNs. We thus measured the frequency
of DCs that incorporate BrdU in LNs from nonimmunized
and immunized mice over a 2 day period. The FITC2DCs
were used as a positive control (Kabashima et al., 2005).
As expected, CD11c+FITC2 DCs became BrdU labeled
(Figure 1D), and cells from CFA/KLH-stimulated LNs in-
corporated BrdU at a greater rate, with about 24% of the
cells becoming BrdU labeled compared to 12% in non-
stimulated LNs. In contrast, FITC+ DCs from nonimmu-
nized or immunized LNs did not incorporate BrdU
(Figure 1D), excluding the possibility that the increased
number of FITC+ DCs in immunized LNs resulted from
proliferation of these cells.
Accumulation of DCs in an activated LN might result
from decreased death of DCs in expanded versus non-
expanded LNs, or a decrease in efferent lymphatic emi-
gration of DCs from the enlarged LNs. However, these
two alternative possibilities are quite unlikely, as they
imply that approximatively 75% of incoming DCs in rest-
ing LNs die immediately upon arrival to the LN (see
Figure 1C, right bar graph; 1.00 2 (13 3 103 FITC+DCs
in nonimmunized mice O 55 3 103 FITC+DC in immu-
nized mice) = 0.76), even while overall numbers of DCs
continue to increase, or, alternatively, that 75% of the in-
coming DCs leave the LN via efferent lymphatics. No dif-
ference in the frequency of apoptotic or dead FITC+ DCs
between nonimmunized and immunized mice was ob-
served (Figure S2).
Typically, approximately only 0.1% of the efferent
lymphatic output is comprised of DCs or macrophages
(Anderson et al., 1981; Bell, 1979), even after stimulation
of DC migration with contact sensitizers (Dandie et al.,
1994). When we collected efferent lymph at the cysterna
chyli (Matloubian et al., 2004) after FITC application to
the entire lower body of nonimmunized mice, we were
unable to detect more than 0.1% FITC+CD11c+ DCs in
efferent lymph (data not shown). Because DCs have
been shown to traffic from the periphery to the blood
via the thoracic duct, and to home to the spleen and
bone marrow (BM) (Cavanagh et al., 2005), we quantified
the number of FITC+CD11c+ DCs in the spleen and the
BM of nonimmunized mice. This complementary ap-
proach confirmed that most of the FITC+DCs remained
in the LNs 18 hr after FITC painting in all conditions in-
vestigated (Figure S3). Thus, the accumulation of DCsin expanded LNs is not due to a decrease in efferent lym-
phatic emigration of DCs from the enlarged LNs.
Increased Migration of Adoptively Transferred
DCs in Expanded Lymph Nodes
The FITC painting assay leads to a robust migratory re-
sponse by DCs, and it is possible that the large number
of migrating DCs fills the entire available niche for in-
coming DCs within the LN such that only an expanded
LN can accommodate more incoming DCs. Therefore,
we tested whether DC migration would be increased un-
der other conditions or assays in which the hypothetical
problem of a ‘‘full niche’’ would not apply. Thus, as a sec-
ond approach to examine DC mobilization to the LNs,
we transferred BM-derived, latex-bead-labeled mature
DCs to the skin and measured their emigration to LNs
(Figure 2A). This transfer method mimics therapeutic
vaccine protocols, and, as expected from relevant
past studies (Berger and Schultz, 2003; Morse et al.,
1999), emigration of BMDCs to resting LN was relatively
lower in magnitude compared with the FITC painting as-
say (Figure 2A). The number of adoptively transferred
BMDCs that migrated to activated LNs was augmented
by more than 3-fold (Figure 2A), although an increased
loss of DCs from the site of injection was not apparent
(Figure 2B). These data confirm that the increase in DC
migration is proportional to the extent of LN expansion,
irrespective of the source of peripheral DCs or the assay
used to trace them. Moreover, increased migration of
adoptively transferred BMDCs pulsed with ovalbumin
was associated with a specific T cell response of overall
greater magnitude (Figure S4).
This method of DC transfer also permitted us to fur-
ther investigate whether the accumulation of DCs in
stimulated LNs was related to an increased survival
and/or retention of transferred DCs in those LNs. To
track the survival of DCs, BMDCs derived from CD45.1
donor mice and pulsed in vitro with latex beads were
transferred into congenic CD45.2 recipient mice, and
the percentage of CD45.1+bead+ and CD45.2+bead+ in
LNs was analyzed by flow cytometry. The detection of
CD45.2+bead+ cells implied that CD45.1+ DCs died after
they reached the LNs and that the bead+ cells were
phagocytized by CD45.2+ recipient cells. One day after
adoptive transfer, about 65% of the cells carrying beads
in nonimmunized and immunized LNs were of donor or-
igin (CD45.1+), suggesting that the majority of the trans-
ferred cells survived at this time point (Figure 2C). At and
after 2 days, the percentage of CD45.1+bead+ cells de-
creased markedly, and this reduction coincided with
an increased frequency of CD45.2+ bead-bearing cells
in both experimental groups (Figure 2C). These results
demonstrated that the survival of transferred DCs in
LNs from immunized mice was similar to nonimmunized
mice (Figure 2C), excluding the possibility that en-
hanced DC migration in stimulated LNs results from an
increase in DC survival.
We next studied the efferent lymphatic emigration of
DCs from LNs 2 days after adoptive transfer by tracing
transferred DCs in the spleen and BM as discussed
above. We detected only 0.002% latex bead+ DCs in
spleen or BM from either nonimmunized or immunized
animals (Figure 2D). The fact that very few adoptively
transferred DCs traffic from the LNs via the efferent
Immunity
206Figure 2. Migration of Adoptively Transferred DCs to Expanded Lymph Nodes
(A) BMDCs (1.63 106 cell/mouse) pulsed with FITC-conjugated latex beads were adoptively transferred to the scapular skin of mice 3 days after
CFA/KLH immunization, and migration of latex-bead-bearing DCs into the brachial LNs was monitored 2 days later.
(B) At this time point, the number of transferred DCs that remained in the site of injection was also evaluated. Significant differences are desig-
nated by *p < 0.05.
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Lymph Nodes
(A) LN sections from control and CFA/KLH
immunized mice were immunostained for
LYVE-1.
(B) LYVE-1+ endothelial cells were analyzed
for coexpression of the proliferation marker
Ki-67 (arrow). Dividing leukocytes were also
observed (arrowhead).
(C) Immunoreactivity for LYVE-1 was exam-
ined in scapular skin from nonimmunized
and immunized mice.
(D) The number of lymphatic vessels/mm2
was determined as well the area covered by
LYVE-1+ vessels (% area) using a computer-
assisted morphometric analysis. Four to five
animals were independently analyzed in
each group, and significant differences are
designated by *p < 0.01. All scale bars, 20 mm.lymph was further confirmed by a second approach
based on the fact that the iliac LN would receive efferent
spillover from the popliteal LN; i.e., FITC dextran in-
jected into the rear footpad drains primarily to the pop-
liteal LN and then to the next proximal iliac LNs via the
efferent lymph (Figure 2E, left panel). When the lym-
phatic vessels to the popliteal LN were severed by re-
moval of the popliteal LN, the iliac LN did not receive
FITC dextran, demonstrating that its afferent lymphatic
connections from the footpad required flow through
the efferent vessels emerging from the popliteal LN
(Figure 2E, right panel). Only 0.01% adoptively trans-
ferred DCs were found in the iliac LNs compared to pop-
liteal LNs (Figure 2F). Only 0.01%–0.1% DCs traversed
nonimmunized LNs in both DC migration assays used
in this study, and this efferent lymphatic emigration of
DCs was not affected by immunization.
Considering that no ‘‘alternative explanations’’ could
account for the greatly increased numbers of DCs that
migrated to inflamed, immunized LNs, we conclude
that the increased accumulation of DCs in expanded
LNs occurs because more DCs from the periphery mi-
grate into those LNs.Induction of Lymphangiogenesis in Expanded
Lymph Nodes
Given the importance of lymphatic vessels in delivering
DCs to LNs, we next wondered if the enhancement of DC
migration in response to LN swelling might be related to
changes in the lymphatic system of that LN. As ex-
pected, lymphatic vessels, identified by LYVE-1 immu-
noreactivity (Jackson, 2004), were mainly located in
the capsule of resting LNs (Sainte-Marie et al., 1982)
and occasionally surrounded a B cell follicle (Figure 3A).
In contrast, the lymphatic architecture was markedly al-
tered in LNs stimulated with CFA/KLH within 3 days
(Figure 3A), the time point at which we initiated DC mi-
gration from upstream locations (Figure 1). Compared
to resting LNs, the network of LYVE-1+ vessels in acti-
vated LNs was greatly expanded in the capsular space
and around B cell follicles. Furthermore, numerous
LYVE-1+ vessels penetrated deeply into the cortex of
the LNs from immunized mice (Figure 3A) and divided
(Figure 3B). A more extended examination of the pheno-
type of LYVE-1+ cells in immunized LNs confirmed that
they were lymphatic vessels and not macrophages (Fig-
ures S5A–S5C).(C) BMDCs derived from CD45.1 mice and pulsed with latex beads were injected in CD45.2 congenic recipient mice. The percentage of
CD45.1+bead+ or CD45.2+bead+ cells in LNs was examined 1, 2, and 7 days after cell transfer.
(D) Two days after adoptive transfer, migration of latex-bead-bearing DCs into the brachial LNs, spleen, and BM was monitored.
(E) FITC dextran was injected in the rear right footpad of nonimmunized mice, and its transport to the popliteal and iliac LNs was examined 30 min
later (left panel, right micrographs). The left footpad was not injected (left panel, left micrographs), or the popliteal LN was removed (right panel).
(F) Similarly, BMDCs pulsed with latex beads were injected in the rear footpad, and their trafficking to these LNs was analyzed.
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immunization was not only accompanied by significant
alterations in the lymphatic vessel network within acti-
vated LNs but also, to a lesser extent, at the upstream
site of DC mobilization. Indeed, the number of lymphatic
vessels as well as the relative area occupied by LYVE-1+
vessels increased in scapular skin from immunized mice
(Figures 3C and 3D).
Effect of Blocking Lymphangiogenesis
on DC Migration
To determine whether enhancement of DC migration
was linked with the expansion of lymphatic vessels,
we evaluated the effect of blocking signaling pathways
that stimulate lymphangiogenesis on DC migration. Be-
cause either vascular endothelial growth factor receptor
2 (VEGFR-2) or VEGFR-3 can mediate the growth of lym-
phatic vessels (Saharinen et al., 2004), we treated the
animals with neutralizing mAbs against VEGFR-2 and/
or VEGFR-3 at doses that are effective in other mouse
models (Baluk et al., 2005; Pytowski et al., 2005).
Treatment with VEGFR-2, VEGFR-3, or a combination
of both antibodies markedly decreased but did not abro-
gate the growth of lymphatics in LNs stimulated with
CFA/KLH (Figure 4A). Consistent with a previous report
(Pytowski et al., 2005), these treatments had no effect on
the preexisting lymphatic network (Figure 4A).
We then examined DC migration induced by FITC sen-
sitization in LNs draining the CFA/KLH injection site or in
distal nonimmunized LNs from mice treated with
VEGFR-2 and/or VEGFR-3 mAbs. Cellularity of LNs
and the basal DC migration in response to FITC sensiti-
zation were not affected by these Abs in distal LNs (Fig-
ures 4B and 4C). In contrast, the blockade of VEGFR-2
and/or VEGFR-3 signaling decreased the number of mi-
grated DC in LNs stimulated with CFA/KLH, compared
to the 6-fold increase in DC migration in immunized
mice receiving rat IgG (Figures 4C and 4D). The blocking
effect of VEGFR-2 alone (46%6 23%) or combined with
VEGFR-3 (48% 6 17%) on DC migration was more effi-
cient than VEGFR-3 alone (32% 6 27%). The effect of
these neutralizing antibodies on DC migration to acti-
vated LNs was greater than their reduction in total LN
cellularity (Figures 4B and 4D).
That the treatment with VEGFR-2 and/or VEGFR-3 an-
tibodies did not affect basal DC migration (Figure 4C) is
consistent with earlier studies reporting that VEGFR-2
signaling does not alter function of DCs (Dikov et al.,
2005) and that skin DCs do not express VEGFR-3 neither
in resting nor inflammatory conditions, in contrast to
corneal DCs (Hamrah et al., 2003). Thus, the inhibition
of DC migration in LNs from immunized mice by admin-
istration of VEGFR-2 and/or VEGFR-3 mAbs is not
likely related to the effect of the mAbs on DCs directly
but rather to the reduction of lymphangiogenesis in
the LN.
Implication of B Cells in Lymph Node Hypertrophy
and Regulation of Lymphangiogenesis
in Response to Immunization
Invading lymphatic vessels were closely associated with
B cells as soon as 2 days after CFA/KLH administration
(Figure 5A). Furthermore, the expansion of LNs in re-
sponse to immunization involved an increase in both Tand B lymphocyte counts, but B lymphocytes increased
proportionally more than T cells (Figure 5B). These ob-
servations prompted us to investigate whether B cells
were critically involved in the LN expansion and in-
creased DC migration induced after immunization.
Therefore, we immunized mMT mice that lack B cells
with CFA/KLH. LN expansion was markedly diminished
in response to CFA/KLH in mMT mice, compared to the
6-fold increase in LN cellularity observed in wt mice
(Figure 5C). In the absence of B cells, there was also
no increase in DC migration to immunized LNs, in con-
trast to wt mice (Figures 5C and 5E). Basal DC migration
Figure 4. Effect of Blocking Lymphangiogenesis on DC Migration
(A) Immunized mice received rat IgG (control) or the combination of
VEGFR-2 and/or VEGFR-3 blocking mAbs and immunoreactivity for
LYVE-1 and B220 were examined in LN sections. All scale bars,
20 mm.
(B and C) The effect of blocking VEGFR-2 and/or VEGFR-3 signaling
on (B) LN cellularity and (C) DC migration induced by FITC applica-
tion was analyzed in nonstimulated distal LNs (None) and stimulated
LNs that drained the site of CFA/KLH injection (CFAKLH). Results
are combined from three experiments, and significant differences
are designated by *p < 0.01 and **p < 0.001.
(D) Results were expressed as fold change over basal cellularity.
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(A) LN sections were double stained for B220 and for LYVE-1. Numerous LYVE-1+ vessels were associated with B cells in immunized LNs (ar-
rowheads).
(B) The total number of T and B cells was determined in brachial LNs from control and CFA/KLH-treated animals.
(C) The effect of CFA/KLH on LN cellularity and DC migration was compared between wt and mMT mice. Results are expressed as means6 SD of
data combined from four experiments. Differences from nonimmunized wt mice were significant, p < 0.001.
(D) The cellularity of LNs from nude mice was compared to control mice before and after CFA/KLH immunization. Migration of DCs was assessed
18 hr after FITC application in both groups of mice. Four animals were independently analyzed in each group, and significant differences from wt
controls were designated by *p < 0.01 and **p < 0.001.
(E) Results were expressed as fold change over basal cellularity.
(F) Immunoreactivity for LYVE-1 was analyzed in immunized LN from mMT mice, nude mice, and their respective controls. All scale bars, 20 mm.to nonimmunized LNs of mMT mice was, however, nor-
mal, indicating that there was not an intrinsic migratory
defect in DCs from mMT mice (Figure 5C). Only the re-
sponse of the LN during immunization was affected in
mMT mice. LN expansion and increased DC migration
also required B cells when a bacterial inoculation was
used to induce LN inflammation (Figure S6).
In contrast to mMT mice, absence of T cells (nude
mice) did not lead to failure of LN expansion in response
to CFA/KLH, although, as expected, the basal cellularity
of LNs from nonimmunized nude mice was reduced by
50% compared to control mice due to the absence of
T cells that normally populate the LN (Figure 5D). Fur-
thermore, the magnitude of DC migration, expressed
as fold change over basal cellularity, was augmented
in immunized nude mice and relatively similar to wt im-
munized mice (Figures 5D and 5E).The lymphatic network induced by CFA/KLH immuni-
zation was considerably reduced in mMT mice but not in
nude mice (Figure 5F). This finding suggests that B cells
play a role in LN lymphangiogenesis in response to CFA/
KLH immunization, and this possibility was further
strengthened by our finding that injection of CpGs,
known as strong B cell activators (Krieg, 2002), leads
to lymphangiogenesis within the LNs in a B cell-depen-
dent manner (Figure S7).
Requirement of B Cell Recruitment to Lymph
Nodes for Induction of Lymphangiogenesis
in Response to Immunization
Because mMT mice lack both immunoglobulin and B
cells, it was not clear in mMT mice whether the LN’s un-
responsiveness to inflammatory immunization was re-
lated to the need for accumulation of B cells in the
Immunity
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sion on B Lymphocytes for Lymph Node Ex-
pansion, DC Migration, and Lymphangiogen-
esis
Chimeric mice were produced by BM trans-
plants (Tx) designed to generate loss of L-se-
lectin selectively in B cells. Recipient mMT
mice were reconstituted i.v. with a mix of
25% wt BM and 75% mMT BM (wt/mMT) or
25% L-selectin KO BM and 75% mMT BM
(LselKO/mMT). Controls included nontrans-
planted wt and mMT mice (No Tx). Six weeks
after reconstitution, mice were treated with
CFA/KLH, and a control group of wt mice,
nontransplanted, was left untreated. (A) LN
sections from immunized mice were immuno-
stained with anti-B220 (green) and anti-CD3
(red) to examine LN architecture. (B) LN ex-
pansion and DC migration as well as (C) lym-
phocyte enumeration were assessed 18 hr af-
ter FITC application. Five animals were
independently analyzed in each group. Differ-
ences from immunized wt/mMT mice were
significant, p < 0.01. (D) LN sections from
nontransplanted and transplanted wt and
mMT mice were immunostained for LYVE-1.
All scale bars, 20 mm.activated LNs or a requirement for antibody. To address
this issue, we generated chimeric mice from mMT hosts
through BM transplantation (Tx) to replenish B cells,
thus restoring Ig deficiency. However, in some animals,
the reconstituted B cells were deficient in L-selectin, an
adhesion molecule required for lymphocyte migration
across HEV of LNs (Gallatin et al., 1983), so they could
not accumulate in LNs. In these chimeric mice, all leuko-
cytes in LN besides B cells were mainly L-selectin+. Re-
cipients of donor chimeric BM were mMT mice. These
mice were reconstituted with a mix of 25% wt BM and
75% mMT BM (wt/mMT, positive control) or 25% L-selec-
tin KO BM and 75% mMT BM (LselKO/mMT). Engraftment
of donor BM was evident from the return of B220+ B cells
and IgM in the circulation of all transplanted mice (data
not shown).
Although the B cell compartment was greatly reduced
in LNs from LselKO/ mMT mice, as expected, LN archi-
tecture was preserved (Figure 6A). Transplantation of
wt BM in mMT mice fully restored the capacity of CFA/
KLH immunization to promote expansion of LNs and in-
creased migration of DC from the periphery (Figure 6B).
When L-selectin expression was selectively deficient in
B cells (LselKO/mMT BM recipients), LNs did not in-
crease in size in response to CFA/KLH, and DC mobiliza-tion was not enhanced (Figure 6B). Homing and accu-
mulation of B and T cells to inflamed LNs was efficient
in mice that received wt B cells, but LN accumulation
of both B and T cells was reduced to baseline levels of
nonimmunized wt mice when B cells lacked L-selectin
(Figure 6C), even though T cells expressed L-selectin,
suggesting that recruitment of B cells may be needed
to coordinate increased recruitment or retention of T
cells. Finally, lymphangiogenesis induced in the LNs af-
ter CFA/KLH immunization was restored in mMT mice by
transplantation of wt BM cells (L-selectin+ B cells),
whereas the growth of new lymphatic vessels was sub-
stantially compromised in LNs when B cell recruitment
was blocked by deficiency in L-selectin (Figure 6D).
These data indicate that B cell recruitment into LNs via
the HEV is strictly required for optimal LN expansion,
lymphangiogenesis, and increased DC migration after
CFA/KLH immunization.
Expression of the Lymphangiogenic Factor
VEGF-A by B Cells
Several factors have been described to promote lym-
phangiogenesis, including VEGF-C, VEGF-A, and angio-
poietins (Saharinen et al., 2004; Tammela et al., 2005).
Because the treatment with VEGFR-3 or VEGFR-2
B Cells Enhance DC Migration
211Figure 7. VEGF-A Expression in Expanded
LN
(A) Immunoreactivity for VEGF-A was studied
in LNs from nonimmunized and immunized
mice.
(B) Sections were double immunostained
with anti-VEGF-A and anti-B220.
(C) Expression of VEGF-A was examined in
immunized LNs from mMT (No Tx), mMT trans-
planted with wt BM (wt/mMT), and mMT trans-
planted with L-selectin KO BM and mMT BM
(LselKO/mMT). All scale bars, 20 mm.
(D) Secretion of VEGF-A by LN B cells stimu-
lated with anti-CD40 and IL-4 or anti-IgM and
IL-4 was quantified by ELISA 48 hr after stim-
ulation. This experiment contained three rep-
licates for each condition tested, and signifi-
cant differences from unstimulated B cells
(none) were designated by *p < 0.005.mAbs inhibited the enhancement of DC migration in
stimulated LNs (Figure 4C), we decided to evaluate the
expression of VEGFR-3 and VEGFR-2 ligands, VEGF-C
and VEGF-A, respectively, in resting and expanded
LNs by immunostaining. In both groups, we did not de-
tect any VEGF-C in LNs (data not shown), but we cannot
eliminate the possibility that this was not due to a techni-
cal issue, although the same antibody has been used in
other studies (Boardman and Swartz, 2003). In contrast,
VEGF-A expression was markedly augmented in immu-
nized LNs compared to nonimmunized LNs (Figure 7A)
and colocalized with B cells (Figure 7B). We next evalu-
ated the consequence of the lack of B cells on VEGF-A
expression. In immunized mMT mice, a faint expression
of VEGF-A was detected, whereas the transplantation
of wt BM in mMT restored the expression of VEGF-A in
B cell follicles (Figure 7C). When L-selectin expression
was selectively deficient in B cells (LselKO/mMT BM re-
cipients), VEGF-A expression was dramatically de-
creased (Figure 7C). These results suggest that B cells
are required for robust VEGF-A expression in the immu-
nized LNs, and, because VEGF-A localized in B cell fol-
licles, we investigated whether B cells themselves could
secrete VEGF-A. Resting B cells did not secrete VEGF-
A, whereas significant amounts of VEGF-A were de-tected when naive B cells were activated ex vivo with
anti-CD40 and IL-4 or anti-IgM and IL-4 for 48 hr
(Figure 7D).
Discussion
Soluble factors produced as a consequence of the in-
flammation that develops at a site of immunization,
such as administration of CFA/antigen, can drain down-
stream through lymphatics and condition the LN to stim-
ulate lymphocyte (Gretz et al., 2000) and monocyte
(Palframan et al., 2001) entry via HEV. Furthermore, im-
munization triggers the remodeling of HEVs to increase
the input of T cells to the LNs (Soderberg et al., 2005).
Here, we provide evidence that, after peripheral admin-
istration of CFA, the lymphatic network within and
around the LN expands. This response apparently per-
mits increased DC trafficking from areas within the ra-
dius of tissue that drains to that LN, not just at the local
site of adjuvant administration. Furthermore, our find-
ings reveal that mobilization of DCs to LNs can be regu-
lated by signals initiated within LNs themselves.
Although it is known that DCs must migrate toward
and enter the lymphatic vessels to reach the LNs,
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between DCs and lymphatic vessels, particularly how
the lymphatic vessel system might affect and control
DC mobilization. Skin DCs likely enter the lymphatic sys-
tem through the dermal initial lymphatic vessels (Stoitz-
ner et al., 2002), which converge into the larger, collect-
ing vessels (Schmid-Schonbein, 1990; Swartz, 2001)
that ultimately deliver lymph and DCs to the LNs.
Examination of how the lymphatic vessels converge
with the structure of the LN reveals, particularly in
mice, that only a few collecting vessels enter and termi-
nate in the subcapsular sinus of the LN, and they branch
extensively at and within the sinus (Randolph et al.,
2005). Although the mouse LN is thought to be rather
simple regarding the lymphatic vessel entry compared
to larger animals, the present study provides evidence
that a more complex lymphatic vessel architecture can
develop under inflammatory conditions, and this expan-
sion of the lymphatic vessel network, which included an
expansion in the periphery as well as the LN, correlates
with alterations in the magnitude of DC accumulation in
that activated LN. Since we did not observe that more
DCs left the peripheral site in the immunized mice, it
seems most likely that expanded lymphatic vessels pro-
vide for more-efficient entry of DCs in the LN. Little is
known about the fate of DCs once they have entered af-
ferent lymphatic vessels. It is often assumed, but not
demonstrated, that most DCs that enter lymphatic ves-
sels are rapidly and efficiently delivered to the T cell
zone of the LN. However, this may not be the case (Ran-
dolph et al., 2005). Our data are consistent with the pos-
sibility that DC delivery to the LN, perhaps from the col-
lecting vessels themselves, may be modulated by the
environmental conditions.
The extent to which DC migration increased after ad-
juvant administration was strictly proportional to the
overall expansion in LN cellularity. It remains to be deter-
mined how such a close relationship between the rela-
tive number of DCs that are mobilized from the periphery
and the relative number of lymphocytes in the LN, most
of which are recruited through HEV, is maintained. As
detailed in Results, we considered several alternative
reasons why a proportional relationship between the
number of migrated DCs and the overall LN cellularity
might be inadvertently observed, including the possibil-
ities that the DC niche filled to capacity such that the
‘‘overflow’’ of DCs either died or emigrated out of the
LN via efferent lymphatic vessels. We also evaluated
the possibility that migrated DCs may proliferate to cre-
ate a population of DCs proportional in number to the
population of lymphocytes in the expanding LN. How-
ever, our analysis fails to support any of these alternative
possibilities. The increase in lymphatic vessels per se
can solely account for this regulation, but our data do in-
dicate that lymphangiogenesis plays an important part.
Indeed, the typical proportional relationship between
overall LN cellularity and DC numbers partly broke
down when we blocked lymphangiogenesis, such that
DC migration was more impaired that LN expansion.
Thus, for DC entry into the LN to keep pace with the in-
creased lymphocyte recruitment after adjuvant adminis-
tration, the expansion of lymphatic vessels is required.
We unexpectedly observed that lymphangiogenesis
and LN expansion, which resulted in increased DC mi-gration, were exclusively dependent on B cells that enter
the LN. In mice that lacked B cells or B cells with the ca-
pacity to home to LNs, LN swelling was not observed
during the first 4 days after immunization in nearby tis-
sue. Although T cells also traffic to LNs, they were inca-
pable of acting redundantly with B cells in initiating LN
enlargement and expansion of the lymphatic vessel net-
work. Furthermore, we show that B cells promote lym-
phatic growth in LNs.
VEGF-C is a lymphangiogenic growth factor that me-
diates its activity through VEGFR-3 or VEGFR-2 and is
often associated with inflammation, wound healing,
and tumor metastasis (Saharinen et al., 2004). The step-
wise proteolytic processing of VEGF-C generates sev-
eral forms of VEGF-C with increased activity for
VEGFR-3, but only the fully processed VEGF-C can acti-
vate VEGFR-2. In the present study, blocking VEGFR-2
signaling reduced the expansion of lymphatic vessel
network and DC migration to activated LNs, whereas
the neutralization of VEGFR-3 had a less pronounced ef-
fect on DC migration. Furthermore, the combination of
mAbs against VEGFR-2 and VEGFR-3 did not inhibit in
a greater manner DC migration and lymphangiogenesis
compared to anti-VEGFR-2 mAb alone. Because only
fully processed VEGF-C binds and activates VEGFR-2
with high affinity, the observed effects may be attributed
to VEGF-C activity. However, it has also been shown
that VEGFR-3 could heterodimerize with VEGFR-2
(Alam et al., 2004), and, thus, blocking VEGFR-2 may
also indirectly affect VEGFR-3 signaling.
Given the important role of VEGFR-2 that our studies
highlight, we must consider along with VEGF-C other li-
gands of VEGFR-2, particularly VEGF-A, as possible me-
diators of the increase in lymphatic vessels and DC mi-
gration observed herein. This connection is indeed
appealing because we show that VEGF-A expression
is very prominently expressed by LN B cells. Moreover,
an increasing body of evidence indicates that VEGF-A
may trigger lymphangiogenesis by a mechanism that re-
mains to be defined (Hirakawa et al., 2005; Nagy et al.,
2002; Ruddell et al., 2003), fitting well with our data dem-
onstrating that blocking VEGFR-2 reduced lymphangio-
genesis and DC migration in response to CFA.
Finally, revelation that B cell-dependent enlargement
of LNs and lymphangiogenesis enhances the mobiliza-
tion of adoptively transferred DCs to LNs, allowing the
priming of T cell response of increased magnitude,
brings forward new strategies to improve vaccination
protocols that involve injection of DCs. A missing step
in these clinical protocols, where poor DC migration is
routinely observed (Berger and Schultz, 2003; Morse
et al., 1999), may be prior conditioning of the LNs to sup-
port more robust migration.
Experimental Procedures
Mice
Six- to eight-week-old female C57BL/6 mice (CD45.2 and CD45.1),
C57BL/6 mice deficient for B lymphocytes (mMT), and C57/BL6
OT-II TCR-OVA transgenic mice on a C57BL/6 background were ob-
tained from Jackson Laboratory (Bar Harbor, Maine). Mice deficient
in L-selectin (L-selectin KO) fully backcrossed on the C57BL/6 back-
ground have been previously described (Robinson et al., 1999).
Athymic nude mice (Ncr-nu/nu) and their age-matched controls
(Ncr-nu/+) were purchased from the National Cancer Institute
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213(Bethesda, Maryland). All studies were approved by the Institutional
Animal Care and Use Committee at Mount Sinai School of Medicine.
Induction of Lymph Node Hypertrophy
Equal volumes of CFA and sterile PBS containing KLH (2.5 mg/ml)
were emulsified (CFA/KLH), and 20 ml of this emulsion was injected
intracutaneously in the front or rear footpads that drain to the bra-
chial and poplitel LN, respectively. Two to four days after the injec-
tion, LNs were removed, and total cell number was evaluated for
each sample using a hemacytometer. Cellular composition was an-
alyzed by flow cytometry by staining with PE-conjugated anti-CD3
and PerCP-conjugated anti-B220/CD45R mAbs (Becton Dickinson
Biosciences). As a second model of LN hypertrophy, 1 3 105 CFU
of Salmonella typhimurium SL7207 provided by M. Rescigno (De-
partment of Experimental Oncology, Milan, Italy) was injected in
the front footpad. As a third model of LN swelling, 60 mg of CpG
was injected in the footpad. The oligonucleotide sequence contain-
ing CpG motif was 50- TCCATGACGTTCCTGACGTT-30, and its con-
trol non-CpG was 50-TCCATGAGCTTCCTGAGCTT-30 (InvivoGen).
Dendritic Cell Migration Assays
To study DC migration, 3 days after CFA/KLH, epicutaneous appli-
cation of FITC was performed on the back skin that drains to brachial
LNs on each side of the mouse (Figure 1A) (Robbiani et al., 2000). To-
tal cell number was evaluated 18 hr later for each sample using a he-
macytometer, and cells were stained with PE-conjugated anti-
CD11c mAb (Becton Dickinson Biosciences) for flow cytometry. To
quantify the migration of DCs induced by FITC application, the total
number of FITC+CD11c+ DCs cells per LN was calculated by multi-
plying the percentage of FITC+CD11c+ cells by the number of total
LN cells (Angeli et al., 2004a). To compare results from different ex-
periments, relative values for individual data points were in some
cases generated by dividing the value of a data point by the mean
of the control from the same experiment.
For adoptive transfer, BMDCs from wt mice prepared as de-
scribed previously (Robbiani et al., 2000) were pulsed with FITC-
conjugated latex beads of 1 mm diameter (Polysciences), and 0.8 3
106 BMDC was injected into each side of the scapular skin 3
days after immunization with CFAKLH. Two days later, cell suspen-
sions from brachial LNs were stained for I-Ab or CD11c, and the en-
tire population of LN cells was acquired by flow cytometry. The total
number of transferred DCs that migrated into LNs was determined
by multiplying the percentage of I-Ab+ or CD11c+ cells carrying latex
beads by the number of total LN cells. To quantify the number of
transferred DCs that remained at the site of injection, red beads
were coinjected with the latex-bead-pulsed DCs since the focal lo-
cation of these bright fluorescent beads made the skin injection
site visible by eye. Areas of the dermis-containing beads were
then processed as described previously (Qu et al., 2004).
BrdU Labeling
Two days after immunization with CFA/KLH, mice were adminis-
tered BrdU (1 mg/mouse) intraperitoneally and then maintained on
water containing 0.4 mg/ml of BrdU for 48 hr. Cells from brachial
LNs were stained with APC-conjugated anti-BrdU Ab using the
BrdU kit from Becton Dickinson.
Analysis of DC Death
Eighteen hours after FITC application, LN cell suspensions were
stained with anti-annexin V (Sigma) and propidium iodide (Sigma),
and the frequency of apoptotic (CD11c+FITC+AnnexinV+PI2) and
dead (CD11c+FITC+AnnexinV+PI+) migrated DCs was analyzed by
flow cytometry. To analyze the death of adoptively transferred
DCs carrying latex beads, we used congenic CD45.1 and CD45.2
C57BL/6 donors and recipients, respectively, that can be distin-
guished by the singular difference in an allele for CD45. BMDCs
from CD45.1 wt mice pulsed with latex beads were injected into
the skin of CD45.2 recipient mice, and the percentage of CD45.1+
and CD45.2+ cells bearing latex beads in draining LNs was deter-
mined by flow cytometry 1, 2, and 7 days after DC transfer.
Immunohistochemistry
Cryostat sections (8–10 mm) from brachial or popliteal LNs were pre-
pared as described previously (Angeli et al., 2004a). For histologicanalysis, sections were stained with hematoxylin and eosin. For im-
munohistochemistry, sequential Ab incubations were for 45 min
each, with Ab incubations separated by three washes in PBS. Pri-
mary antibodies used included biotinylated anti-CD3 and CD31
(Becton Dickinson Biosciences), anti-B220 (Caltag), anti-LYVE-1
(Upstate), anti-CD31 (Serotec), anti-VCAM-1 (cloneM/K2.7), anti-
VEGF-A and VEGF-C (Santa Cruz), and anti-Ki-67 (Dako). Cy3-con-
jugated streptavidin (Sigma), Cy2- or Cy3 -conjugated anti-rat, and
Cy3- or FITC-conjugated anti-rabbit mAbs (Jackson Immunore-
search) were used for detection. Endogenous avidin and biotin
were inhibited with the blocking kit from Vector. Detection of
VEGF-C and VEGF-A was conducted by using the peroxydase-me-
diated tyramide amplification kit (PerkinElmer) and Cy3-conjugated
streptavidin (Sigma). To determine the area covered by LYVE-1 ves-
sels, images of representative sections stained for LYVE-1 from
scapular skin were acquired with a Spot digital camera (Diagnostic
Instruments), and computer-assisted morphometric of lymphatic
vessel was performed using the IP-LAB software (Scanalytics).
The density of LYVE-1+ lymphatic vessel expressed as lymphatic
vessel/mm2 was determined using a grid.
Detection of Lymphatic Vessels via Microlymphangiography
To visualize lymphatic vessels postfixation in LN sections, 10 ml of
1% solution of FITC-conjugated, lysine-fixable dextran (500 kDa,
Molecular Probes) was injected intradermally into the front footpad
1 hr before analysis. A similar experiment was performed to visualize
popliteal and iliac LNs.
Inhibition of VEGF Receptor Signaling
Signaling by VEGFR-2 and VEGFR-3 was inhibited using selective
blocking rat mAbs from clones DC101 and mF4-31C1 (Imclone Sys-
tems Inc.), respectively. Rat IgG was used as a control. Antibodies
were injected i.p. in mice on the day of and 2 days after CFA/KLH ad-
ministration at a dose of 0.8 mg/mouse (Baluk et al., 2005; Pytowski
et al., 2005).
Transplantation of BM Cells
Six-week-old recipient mMT mice were lethally irradiated with two
doses of 500 rad 2 hr apart and injected intravenously with a total
of 10 3 106 BM cells as described previously (Merad et al., 2002).
Two experimental groups of five mice each were designed: mMT
that received a mix of 25% wt BM and 75% mMT BM (wt/mMT) or
25% L-selectin KO BM and 75% mMT BM (LselKO/mMT). Six weeks
after transplantation, mice were treated with CFA/KLH as described
above. Control mice included nontransplanted wt and mMT mice.
T Cell Proliferation Assay
Spleen and LNs cells from OT-II TCR-OVA C57BL/6 mice were la-
beled with 5 mM carboxylfluorescein-succinimydil-ester (CFSE),
and 10 3 106 CFSE-labeled cells were injected i.v. in wt C57BL/6 4
days after immunization. Two days after CFSE+ cell transfer, 2 3
105 DC BM-derived DCs pulsed with 20 mg/ml of OVA were injected
on the scapular skin of mice. Four days after DC transfer, OVA-spe-
cific CD4+ T cell proliferation in brachial LNs was traced by following
the dilution of CFSE labeling by flow cytometry. Propidium iodide
was added immediately prior to FACS analysis for exclusion of
dead cells.
B Lymphocyte Purification and In Vitro Stimulation
B lymphocytes were isolated from LN of nonimmunized wt mice us-
ing a negative selection kit from Dynal. Purified B lymphocytes (1 3
106 cell/ml) (purity >90%) were stimulated with anti-CD40 mAb
(clone FGK) and IL-4 (R&D Systems) or anti-IgM (Fab02 fragment,
Jackson Immunoresearch) and IL-4. Supernatants were collected
48 hr later to measure the levels of VEGF-A using the ELISA kit
from R&D Systems.
Statistics
Statistical comparisons were made using the Student’s two-tailed t
test. Results are expressed as means 6 SD. All experiments con-
tained three to four replicates per experimental parameter.
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Supplemental Data include seven figures and Supplemental Refer-
ences and can be found with this article online at http://www.
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